Thermo Fisher Scientific (TMO) will likely update its growth plan on its upcoming analyst day, but there might not be any commentary on 2025, UBS Securities said in a note email Monday.

"We're expecting Thermo Fisher's upcoming analyst day to provide an in-depth look into the various business lines of the company's diversified portfolio," UBS said, with the company focusing on services, proteomics, the commercialization and weight-loss drugs.

UBS said it is keen to understand the impact of its 2025 GLP-1 contract on growth and the evolution of its commercial engine, which accelerates growth for previously slow-moving product lines.

Thermo Fisher's acquisition of Olink Holding (OLK) strengthens its leadership in mass spectrometry and high-plex proteomics, with potential for cross-selling between its instruments and new proteomics platform, UBS said.

UBS revised the company's 2024 and 2025 EPS estimates to $21.62 and $23.27, down from $21.67 and $23.76.

UBS raised its price target for Thermo Fisher to $700 from S$670, with a buy rating.

Price: 615.37, Change: +4.20, Percent Change: +0.69